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Background:  Deﬁnitive  identiﬁcation  of  poliovirus  strains  in vaccines  is essential  for  quality  control,  par-
ticularly  where  multiple  wild-type  and  Sabin  strains  are  produced  in  the  same  facility.  Sequence-based
identiﬁcation  provides  the  ultimate  in  identity  testing  and  would  offer several  advantages  over  serological
methods.
Methods:  We  employed  random  RT-PCR  and  high  throughput  sequencing  to recover  full-length  genome
sequences  from  monovalent  and  trivalent  poliovirus  vaccine  products  at various  stages  of  the  manufac-
turing  process.
Results: All  expected  strains  were  detected  in  previously  characterised  products  and  the  method  permit-
ted  identiﬁcation  of  strains  comprising  as little  as  0.1%  of  sequence  reads.  Highly  similar  Mahoney  and
Sabin  1  strains  were  readily  discriminated  on  the  basis  of speciﬁc  variant  positions.  Analysis  of  a  product
known  to contain  incorrect  strains  demonstrated  that  the  method  correctly  identiﬁed  the  contaminants.
Conclusion:  Random  RT-PCR  and  shotgun  sequencing  provided  high  resolution  identiﬁcation  of  vaccine
components.  In addition  to  the  recovery  of  full-length  genome  sequences,  the  method  could  also  be  easily
adapted to the  characterisation  of  minor  variant  frequencies  and  distinction  of  closely  related  products
on the basis  of  distinguishing  consensus  and  low  frequency  polymorphisms.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
Rapid and accurate identiﬁcation of poliovirus strains present in
accines is important to ensure correct antigenic proﬁle and limit
he risk of an incorrect virus strain being included in a ﬁnal product.
he latter is a particular concern in cases where both attenuated
Sabin) poliovirus strains destined for oral and/or inactivated polio
accine and wild-type strains destined only for inactivated vaccines
r used as controls for quality control testing are handled on the
ame site.
Serological identiﬁcation of vaccine components has been used
ffectively [1] and is the identiﬁcation method approved in the
uropean Pharmacopoeia [2], however this approach may  be
imited by the availability of appropriate reagents and inter-lab
ariation, may  not distinguish between wild-type and attenuated
trains of the same serotype and will not distinguish between virus
trains that differ by a small number of nucleotides and/or amino
cids. Resolution to the nucleotide level is useful not only in a
rospective monitoring setting, but may  also assist in tracing the
∗ Corresponding author. Tel.: +44 1707 641191.
E-mail address: edward.mee@nibsc.org (E.T. Mee).
ttp://dx.doi.org/10.1016/j.vaccine.2015.05.052
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article usource should a contaminant be detected. It also has the advantage
that the nucleotide sequence of a given sample will be invariant
regardless of the reagents and methods used for its determina-
tion. Several methods have been developed for identiﬁcation of
poliovirus strains at the molecular level, the most advanced of
which was  recently described by Nijst et al. [3]. This method,
based on quantitative reverse transcriptase (RT)-PCR offers sev-
eral advantages over serological testing including high speciﬁcity.
It provides, however, information about only a small region of the
genome (typically the 60–80 nucleotides constituting the primer
and probe sequences), requires multiple reactions per sample to
cover all possible strains and serotypes and has lower sensitivity
for serotype 1 than for serotypes 2 and 3 [3].
Genome sequencing would provide the ultimate identity test.
The availability of rapid, high-throughput benchtop sequencers
makes full genome sequencing of multivalent vaccine samples fea-
sible, with a tiny fraction of the time, effort and cost previously
required. We evaluated a sequence-independent RT-PCR [4] and
shotgun sequencing approach for the unambiguous identiﬁcation
of poliovirus strains present in a variety of inactivated poliovirus
vaccines. All expected strains were detected in live and inactivated
monovalent intermediates and inactivated trivalent ﬁnal products.
Retrospective testing demonstrated that the sequencing approach
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table 1
Vaccine material.
Vaccine Trivalent product Monovalent product Live/inactivated Extraction
A sIPV A Inactivated MinElute
A-s1 Live vRNA
A-s2 Live vRNA
A-s3 Live vRNA
A-s1IPV Inactivated vRNA
A-s2IPV Inactivated vRNA
A-s3IPV Inactivated vRNA
B B-s1 Live vRNA
B-s1IPV Inactivated MinElute
B-s2 Live vRNA
B-s2IPV Inactivated MinElute
B-s3 Live vRNA
B-s3IPV Inactivated MinElute
C  cIPV C Inactivated MinElute
C-c1IPV Inactivated MinElute
C-c2IPV Inactivated MinElute
C-c3IPV Inactivated MinElute
D  cIPV D Inactivated MinElute
D-c1 Live vRNA
D-c1IPV Inactivated MinElute
D-c2 Live vRNA
D-c2IPV Inactivated MinElute
D-c3 Live vRNA
D-c3IPV Inactivated MinElute
E  cIPV E Inactivated MagNA Pure
F  sIPVsample Inactivated MinElute
s Sabin; c conventional; IPV inactivated polio vaccine; vRNA QIAMP viral RNA Mini Spin Kit; MinElute Qiagen MinElute Virus Spin Kit; MagNAPure MagNA Pure LC total RNA
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csolation kit.
llowed for detection and characterisation of contaminating strains
n an IPV product. This technique has the advantages of requir-
ng only a single assay per sample, distinguishing between closely
elated strains and providing information on the full genome
equence of virus strains in a vaccine.
. Methods
.1. Vaccines
Samples were commercial vaccine components from different
anufacturers, sampled at various stages of manufacturing: live
onovalent samples, fomaldehyde-inactivated monovalent sam-
les and trivalent formaldehyde-inactivated pools equivalent to
he ﬁnal vaccine product. Vaccine characteristics are described in
able 1.
.2. Nucleic acid extraction
RNA was extracted using QIAMP vRNA Mini Spin columns or
IAMP MinElute Virus Spin Kit (Qiagen) without the addition of car-
ier RNA. One sample was extracted using the Kingﬁsher automated
article processor (Thermo Electron Corporation) and a MagNA
ure LC Total Nucleic Acid Isolation Kit (Roche), incorporating
roteinase K digestion, following the manufacturer’s instructions.
ater only controls were extracted, ampliﬁed and sequenced in
arallel with each set of samples.
.3. Sequence-independent RT-PCR
Sequence-independent ampliﬁcation was performed following
he method of Victoria et al. [5]. cDNA was synthesised using the
uperScript III 1st strand cDNA synthesis kit (Life Technologies),
ith 8 l RNA and 100 pmol primer K-N8 (5′-GAC CAT CTA GCG ACC
CC CAN NNN NNN N-3′), generating randomly primed ﬁrst strand
DNA with an arbitrary 5′ tagging sequence. 10 l of the ﬁrst strandreaction was added to 50 l second strand mix  containing 100 pmol
primer K-N8 (to randomly prime second strand synthesis and add
the same arbitrary 5′ tagging sequence), 150 M dNTPs (Roche) and
5 U Large (Klenow) Fragment DNA Polymerase in 1× REACT2 buffer
(Life Technologies). The reaction was incubated at 37 ◦C for 1 h fol-
lowed by 75 ◦C for 20 min, resulting in double-stranded cDNA with
the tagging sequence ‘K’ at both ends. PCR was performed using
2.5 l of cDNA in a 25 l reaction containing 0.7 M primer K (the
arbitrary tag introduced during cDNA synthesis, 5′-GAC CAT CTA
GCG ACC TCC CA-3′) and Kapa HiFi HotStart Ready Mix  (Anachem).
Ampliﬁcation conditions were: 98 ◦C for 60 s; 30 cycles of 98 ◦C
for 20 s, 60 ◦C for 30 s, 72 ◦C for 30 s; 72 ◦C for 5 min. Ampliﬁed
products, comprising fragments of variable length and theoretically
representing an unbiased sample of all nucleic acid in the sam-
ple, were visualised by ethidium bromide staining on agarose gels.
A representative gel is shown in Supplemental Fig. S1. Products
werepuriﬁed using AMPure XP magnetic beads (Beckman Coulter),
quantiﬁed using Qubit High Sensitivity dsDNA assay (Life Technolo-
gies), analysed on an Agilent High Sensitivity DNA chip (Agilent)
and diluted to 0.2 ng/l in molecular grade Tris–EDTA, pH8.0.
2.4. Sequencing
Sequencing libraries were prepared using Nextera XT reagents
(Illumina) and the manufacturer’s protocol, and sequenced on a
MiSeq using a 2 × 251 paired-end v2 Flow Cell (Illumina). Six to 10
vaccine samples were pooled for each run.
2.5. Primer, quality trimming and assembly
Raw sequence data were imported into Genious R7 (Biomatters)
and paired end reads combined. Data were ﬁltered and aligned
using a custom workﬂow with the following parameters: shotgun
primer K and Nextera adaptor/index sequences were trimmed
from 5 and 3′ ends with a minimum 5 bp overlap; reads were
trimmed to have an average error rate <1%, no more than one base
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Table  2
Reference sequences used for assembly.
Serotype Strain Reference length Accession number Notes
1 Mahoney 7440 V01149
Sabin 1 7441 V01150
2 MEF-1 7440 AY238473
Sabin 2 7439 AY184220
3 Saukett 7429 KP247597 Full-length sequence
constructed from live serotype
3  vaccine samples
Sabin 3 7432 AY184221
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all three serotypes (Fig. 3). Coverage proﬁles did not appear to be
affected by the extraction method.ith a quality of <Q20 and no ambiguities; reads shorter than 100
ases were removed. Reads were then mapped to references as
eﬁned in Table 2, with a minimum 50 base overlap, minimum
verlap identity of 90%, maximum 10% mismatches per read,
llowing up to 10% gaps, word length of 18 and index word
ength of 13. Reads with equally good matches to more than one
eference were assigned randomly to one or the other. Results
ere displayed using Prism v5.02 (GraphPad Software).
.6. D Antigen quantiﬁcation
D Antigen content relevant of trivalent IPV products was  deter-
ined using a standard control testing method [1].
.7. Distinction of Mahoney and Sabin 1 strains
Reference consensus sequences for VP1 were obtained by map-
ing reads from live monovalent samples of known identity (90%
onsensus using highest quality base) against the VP1 region
nucleotide positions 2480 to 3385) of the Sabin 1 or Mahoney
eferences described in Table 2. The Sabin 1 virus was  derived
rom the parental Mahoney strain by repeated passage through
onkeys and cell culture [6], and the reference sequences differ
rom each other by ∼57 nucleotides across the whole genome and 9
ucleotides in the VP1 region. The consensus sequence for Mahoney
P1 differed from reference strain (accession number V01149) at
wo positions in all vaccine viruses (nucleotide positions 2545 and
626 of the whole genome sequence, corresponding to nucleotide
ositions 66 and 147 of the VP1 coding sequence). This modi-
ed sequence was used for subsequent analysis. For distinction
etween Mahoney and Sabin 1 strains, reads were assembled to the
onsensus VP1 coding sequence of the references in Table 2 using
he assembly parameters described above. Consensus sequences
ere then extracted (90% consensus using highest quality base),
ligned using Clustal W and examined to identify the serotype 1
omponent.
. Results
.1. Effect of virus inactivation on sequence read mapping
We  initially compared sequencing results from pre-inactivation
nd post-inactivation monovalent samples extracted using the
IAMP vRNA Mini Spin Kit. Pre-inactivation, greater than 99% of
ltered reads mapped to the corresponding reference sequence.
ost-inactivation, the percentage of ﬁltered reads mapping to
oliovirus was greatly reduced (range 0.14–87.5%), with clear
ifferences between vaccine products (Fig. 1). The use of pro-
einase during RNA extraction was expected to improve recovery
f poliovirus RNA; hence multiple extraction methods were com-
ared.3.2. Selection of RNA extraction method
We compared sequencing results obtained with inactivated
samples extracted using either the vRNA Mini Kit or the QIAMP
MinElute Virus Spin Kit, the latter incorporating a proteinase K
digestion step. No difference in overall sequence quality (assessed
as percentage of reads passing adaptor/quality trimming) was
observed between the kits (though it is noted that inter-run and
inter-sample variability was  high, Fig. 2A), however a much greater
proportion of ﬁltered sequencing reads mapped to the correspond-
ing poliovirus reference in samples processed using the QIAMP
MinElute Virus Spin Kit (p = 0.001, Wilcoxon signed rank test,
Fig. 2B).
3.3. Sequence coverage of vaccines ampliﬁed by
sequence-independent RT-PCR
Depth of coverage for live poliovirus varied across the genome
and between serotypes, consistent with other reports employing
random RT-PCR ampliﬁcation of total nucleic acid [4,7]. The most
even coverage was obtained for live Sabin 3, while inactivated virus
preparations were characterised by markedly uneven coverage forFig. 1. Comparison of pre- and post-inactivation monovalent IPV samples. RNA was
extracted with QIAMP viral RNA Mini Spin Kit and random RT-PCR products
sequenced and mapped to poliovirus reference strains. s Sabin, c conventional, live
pre-inactivation monovalent virus, IPV inactivated monovalent virus.
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Fig. 2. Comparison of extraction methods for recovery of high-quality sequence data from IPV. RNA was  extracted using either QIAamp vRNA Mini Kit or QIAamp MinElute Virus
Spin  Kit and sequenced as described in methods. (A) Percentage of total reads passing trimming and quality ﬁlters. (B) Percentage of ﬁltered reads mapping to poliovirus
reference sequences. Methods were compared using a Wilcoxon signed rank test.
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Saukett (Fig. 7). Analysis of VP1 sequences conﬁrmed the serotype
1 strain as Sabin 1 (Table 3), consistent with previous work (JM,
unpublished data). Although this assay is not suitable for conclu-
sively demonstrating the presence of live virus, coverage of the
Table 3
Distinction of Sabin 1 and Mahoney strains by analysis of VP1 consensus sequences.
Sample Sabin-speciﬁc
positionsa
Mahoney-speciﬁc
positionsa
sIPV A 9 –
A-s1 9 –
A-s1IPV 9 –
B-s1 9 –
B-s1IPV 9 –
cIPV C – 9
C-c1IPV – 9
cIPV D – 9
D-c1 – 9.4. Threshold for identity testing
Following quality ﬁltering, reads were mapped against all Sabin
nd wild-type poliovirus vaccine strains at high stringency (90%
ucleotide identity with a minimum 50 nucleotide overlap). For all
onovalent live viruses, the proportion of reads mapping against
he expected genome sequence exceeded 90% (including aggregate
ounts for reads mapping to Sabin 1 and Mahoney) (Fig. 4). The
roportion of reads mapped to the expected poliovirus sequence
or the corresponding inactivated monovalent samples was lower
nd more variable (range 4.9–88% of ﬁltered reads). For trivalent
roducts, the proportion of reads mapping to each serotype varied
etween manufacturers (presumably reﬂecting the different con-
entration of individual viruses) but in all cases exceeded 1% of
ltered reads. In no case did more than 0.1% of ﬁltered reads map
o unexpected poliovirus reference sequences.
.5. Genome coverage of vaccine components
Typically, 100% (and in all cases greater than 90%) of the target
enome was sequenced for expected vaccine components (Fig. 5)
ith depth of coverage ranging from 100 to 80,000 reads per
ucleotide. In some samples, a small proportion of reads also
apped to unexpected poliovirus genomes. In some cases these
eads covered large sections of the unexpected poliovirus genome,
owever low coverage (typically 0–5 reads per nucleotide) and
arge numbers of SNPs in the aligned regions (data not shown),
ndicated that these reads were mapped to regions of high simi-
arity to the expected vaccine component rather than representing
ncorrect strains in the vaccine. The percentage of target genome
equenced alone did not therefore provide a reliable cut-off for
ssigning identity to a given vaccine component.
.6. Distinction of Sabin 1 and Mahoney strains
The high degree of similarity (>99% nucleotide identity) between
abin 1 and Mahoney strains of poliovirus resulted in large numbers
f Mahoney reads mapping to the Sabin 1 reference sequence and
ice versa. Increasing the stringency of mapping above 90% resulted
n fewer reads overall mapping to both reference sequences but
nambiguous mapping could not be achieved even at 100% iden-
ity (data not shown). To conﬁrm the identity of serotype 1 viruses,
onsensus sequences were extracted from the VP1 region (contain-
ng nine distinguishing nucleotide differences) of mapped reads
nd aligned against the Mahoney and Sabin 1 reference sequences.In all cases, the consensus base at all nine positions matched the
expected sequence (Table 3).
3.7. Correlation between number/proportion of mapped reads
and D antigen content
Potency data, based on D Antigen content, were available for
all trivalent vaccines tested. Potency data were plotted against
percentage of reads identiﬁed as each strain; a general trend for
increasing percentage of reads mapped with increasing D Antigen
concentration was  apparent, however a signiﬁcant correlation was
observed only for serotype 3 (Fig. 6).
3.8. Detection of contaminating strains in a Sabin IPV vaccine
To evaluate the performance of the assay we analysed an inactiv-
ated Sabin poliovirus vaccine that was  previously found to be
contaminated with live Sabin 1 and inactivated wild-type strains
of poliovirus. Previous investigations determined the presence of
wild-type serotype 2 MEF-1, wild-type serotype 3 Saukett and live
Sabin 1 as well as the expected inactivated Sabin strains (JM, unpub-
lished data). The vaccine was  at the Research and Development
phase and was removed from any further pre-clinical development.
At a threshold of 0.1% of ﬁltered reads, the assay correctly identiﬁed
Sabin 1-3, wild-type serotype 2 MEF-1 and wild-type serotype 3D-c1IPV – 9
cIPV E – 9
sIPV vaccine 9 –
a Based on 9 unique positions in the 906 nucleotide sequence of VP1.
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Fig. 3. Coverage of Sabin poliovirus genomes following random RT-PCR and sequencing of vaccine D. Filtered reads from (A) Sabin 1, (B) Sabin 2 and (C) Sabin 3 monovalent
samples were mapped against reference genome sequences and percentage of maximum coverage reported. Grey live virus, red inactivated sample extracted with QIAamp
vRNA  Mini Kit, blue inactivated sample extracted with QIAamp MinElute Virus Spin Kit. (For interpretation of the references to colour in this ﬁgure legend, the reader is
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(eferred  to the web  version of this article)
abin 1 was comparable to the proﬁle of a live virus established
reviously (Fig. 3A and Supplemental Fig. S2).
.9. Characterization of unmapped reads
A subset of unmapped reads for all samples were assembled and
earched against the NCBI nt database; the majority of matches
ere to poliovirus or closely related coxsackievirus strains, with
on-viral hits being predominantly human and bovine, likely
eﬂecting the cells and serum using during propagation of the virus
data not shown).4. Discussion
We have developed an identity test based on whole genome
sequencing of inactivated poliovirus vaccines. The sequence-
independent ampliﬁcation approach employed here has the
advantage of not requiring prior knowledge of the vaccine com-
position, does not require modiﬁcation for different vaccine
components and should not suffer bias or ampliﬁcation failure due
to sequence differences in primer binding regions. The method
is more technically demanding than serological testing in its cur-
rent format and will require further development and validation to
3538 E.T. Mee et al. / Vaccine 33 (2015) 3533–3541
Fig. 4. Mapping and genome coverage of IPV samples. Filtered reads from monovalent and trivalent samples of vaccines A–E were mapped against poliovirus reference
sequences. (A) percentage of reads mapped to poliovirus references in monovalent live and inactivated samples. (B) percentage of reads mapped to poliovirus references
in  trivalent inactivated samples. (C) percentage of reads mapped to poliovirus references in parallel water controls. Letters indicate corresponding vaccine sample. nd Not
done.  Solid colours indicate wild-type virus, light colours indicate Sabin virus; white indicates unmapped reads. (For interpretation of the references to colour in this ﬁgure
l
s
t
o
c
s
a
r
a
y
t
b
r
p
e
m
t
p
u
h
l
t
f
p
iegend,  the reader is referred to the web version of this article)
urpass serological testing as the gold standard method for iden-
ity testing. Nevertheless, the considerable gain in the amount
f information obtained, and likely reductions in assay time and
omplexity due to further advances in library preparation and
equencing technology suggest the method has potential to become
 routine part of the quality control process for IPV.
Preliminary experiments using vRNA extraction columns and
andom RT-PCR revealed low and inconsistent coverage of inactiv-
ted samples. Formaldehyde treatment is known to reduce cDNA
ields from inactivated poliovirus vaccines [8] and we  reasoned
hat cross-linking of RNA to protein may  prevent RNA from
inding to the spin column. Differences between products may
eﬂect varying degrees of RNA modiﬁcation due to different
article:formaldehyde ratios during inactivation (JM and oth-
rs, unpublished observations). The greater proportion of reads
apped when proteinase K digestion was used suggested that
his method is preferable for recovery of RNA from inactivated
oliovirus samples. Genome coverage of inactivated samples was
neven with no improvement with proteinase K digestion. Areas of
igh and low coverage may  result from secondary structure and/or
ocal RNA–protein interactions affecting the sensitivity of the RNA
o formaldehyde treatment.Expected poliovirus genome sequences were readily recovered
rom inactivated trivalent vaccines. Reads mapping to unexpected
oliovirus genomes were typically located in regions of high sim-
larity between wild-type and Sabin strains, and were readilyapparent due to low and uneven genome coverage and the pres-
ence of large numbers of SNPs. A trivalent Sabin IPV previously
found to be contaminated with live Sabin 1 and inactivated MEF-1
and Saukett was  tested and both MEF-1 and Saukett were readily
detectable. The expected Sabin 3 was present in only 0.1262% of
reads reﬂecting the fact that the contaminating Saukett was present
in greater abundance than the Sabin strain (JM, unpublished data).
Unambiguous mapping of reads to either Sabin 1 or Mahoney
was challenging due to the high similarity between the two strains.
By analysis of VP1 consensus sequences, the correct strain could be
readily identiﬁed. This approach would not necessarily detect low
level contamination of the serotype 1 component of the vaccine;
however such contamination could be detected by variant calling
within the mapped read set.
Reads in vaccines mapping to unexpected poliovirus genomes
result from several causes. The simplest-similarity between Sabin
and wild-type strains likely explains the vast majority of back-
ground reads. A higher mapping stringency would address this at
the expense of a greater number of unmapped reads. Background
reads in water controls are more of a concern but are explica-
ble. The vast number of reads obtained by modern sequencing
methods means that the detection of even trace levels of con-
tamination occurring during sample extraction, ampliﬁcation and
library preparation is possible. Running and analysing parallel no-
template controls from the extraction stage is therefore essential
in every assay.
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Fig. 5. Genome coverage of poliovirus references in IPV samples. Filtered reads from monovalent and trivalent samples of vaccines A–E were mapped against poliovirus reference
sequences. Graphs indicate percentage of indicated genome with ≥1× coverage. Solid colours indicate wild-type virus, light colours indicate Sabin virus. (For interpretation
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Correlation between D Antigen content and percentage of
equence reads mapped was poor, likely due to the nature of the
ssays: D Antigen is assayed for each serotype independently while
roportions of sequencing reads mapped are interdependent. It is
nlikely, therefore, that a sequence based approach would offer an
lternative to D Antigen quantiﬁcation.
Since the method recovers full-length genome sequence, the
onsensus sequence of each serotype can be compared against
he reference and previous batches, as a measure of batch-to-
atch consistency. Changing proportions of SNPs over time may
lso provide an indication of deviations within the production pro-
ess. Both full-length consensus sequences and SNP proﬁles may
lso provide useful information about the source of a contaminant,
hould one be detected. In this study the consensus sequences of
abin strains 1 and 2 and Saukett were invariant, but the Mahoney,
EF-1 and Sabin 3 strains contained ∼50, 5 and 4 positions,of this article)
respectively, that varied between different products (data not
shown) and from the reference sequence. Information about the
potential source of environmental poliovirus, e.g. due to acciden-
tal release such as that occurring recently in Belgium [9] could
also be obtained using this approach following the identiﬁcation
of contamination by routine screening methods.
A further development of the assay would permit screening
for adventitious agents. Such assays require reﬁnement, but the
approach has already proven capable of detecting adventitious
agents in a live attenuated vaccine [4]. Non-poliovirus sequences
were detected in all samples tested in the current study. These
included sequences of bovine and human origin, reﬂecting the
host cells used for virus propagation and bovine viral diarrhoea
virus and bacterial and eukaryotic hits likely arising from reagent
contamination [10–12]. The lower efﬁciency of ampliﬁcation
from formaldehyde treated samples [8] may  result in apparent
3540 E.T. Mee et al. / Vaccine 33 (2015) 3533–3541
Fig. 6. Correlation between D Antigen content and percentage of reads mapping against
poliovirus references. D antigen content of vaccines was compared to percentage of
r
(
o
h
p
f
v
M
n
g
i
d
l
a
sIPV H2O controlA
B
sIPV H2O control
0
20
40
60
80
100
Mahoney
Sab in 1
MEF-1
Sab in 2
Saukett
Sab in 3
Pe
rc
en
ta
ge
 o
f g
en
om
e 
co
ve
re
d
Fig. 7. Identity testing of a trivalent sIPV product. Sample and water control were
sequenced following random RT-PCR and reads mapped against poliovirus refer-
ences. (A) percentage of ﬁltered reads matching poliovirus references sequences.
duction. J Virol Methods 2013;189(Apr (1)):189–95. S0166-0934(13)00051-7eads mapped to each poliovirus reference using linear regression. (A) Serotype 1,
B)  Serotype 2, (C) Serotype 3.
ver-representation of contaminating reads in such samples,
owever similar classes of non-poliovirus sequence reads were
resent in both live and inactivated samples.
In summary, we have demonstrated the utility of a method
or identiﬁcation of all poliovirus strains in trivalent inactivated
accines (and upstream monovalent bulks) within a single assay.
ahoney and Sabin 1 strains could be distinguished and contami-
ants readily identiﬁed. The ability to reconstruct near full-length
enome sequences even from inactivated products also provides
mportant sequence information that may  assist not only with
etection of contaminants, but also with identifying or excluding
ikely sources. The assay can likely be adapted to identity testing of
ny nucleic-acid containing vaccine product.(B) percentage of reference sequence genome covered. Two wild-type strains (MEF-
1  and Saukett) were detected in addition to the expected Sabin sequences. The VP1
consensus sequence for serotype 1 matched Sabin 1.
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